What is the Microbacterium ABM complex?

What is the “Microbacterium ABM complex”?

Microbacterium “ABM complex” is not an established clinical entity; the term is likely a misnomer or confusion with Mycobacterium avium complex (MAC) or with Microbacterium spp., which are environmental coryneform Gram-positive rods that rarely cause human infection. 1

• Clarify the organism:
  • If the lab meant Mycobacterium avium complex (MAC), follow ATS/IDSA NTM guidance for diagnosis/treatment because MAC can cause clinically significant pulmonary or disseminated disease and impacts morbidity, mortality, and QOL when untreated 1.
  • If the lab meant Microbacterium spp. (genus Microbacterium, family Microbacteriaceae), these are environmental organisms occasionally implicated in catheter-related or opportunistic bacteremia in immunocompromised hosts; confirm true infection vs contamination before treating, as over-treatment can harm QOL without mortality benefit 2, 3, 4.

Algorithm to resolve and manage (prioritize morbidity/mortality/QOL)

1. Verify identification (highest priority step)

• Contact microbiology to:
  • Confirm genus/species by MALDI-TOF or sequencing; ask explicitly if “Mycobacterium avium complex (MAC)” vs “Microbacterium spp.” 1, 5.
  • Review acid-fast stain, growth rate, and culture media (AFB vs routine) to distinguish NTM (Mycobacterium) from Microbacterium.

1. If MAC (Mycobacterium avium complex) is confirmed

• Do not start empiric therapy for suspected NTM lung disease until diagnostic criteria met (to avoid toxicity and resistance) 1.
• Diagnose using ATS/IDSA criteria (symptoms, imaging, and microbiology). Once criteria met, treat with multidrug macrolide-based regimen; avoid monotherapy to prevent macrolide resistance, which worsens outcomes 1, 6.
• Duration: typically 12 months beyond culture conversion; involve experts for complex cases to optimize survival and QOL 1, 6.

1. If Microbacterium spp. is confirmed

• Assess clinical significance:
  • True infection more likely with: multiple positive blood cultures, indwelling catheter, immunosuppression, or compatible syndrome; otherwise consider contaminant to avoid unnecessary toxicity 2, 3, 4.
• Source control first:
  • For catheter-related bloodstream infection, follow catheter-infection guidelines: obtain paired blood cultures, consider catheter removal if local infection or persistent bacteremia; treat 10–14 days if uncomplicated and longer for complications to reduce relapse/mortality 7.
• Antibiotics:
  • No standardized regimen; many isolates are susceptible to agents for Gram-positive rods. Use susceptibilities to choose therapy; case series show favorable outcomes when guided by testing 3, 4.
  • Avoid prolonged therapy without proof of true infection to protect QOL.

Nuances and pitfalls

• Pitfall: Confusing “MAC” (Mycobacterium avium complex) with “Microbacterium” leads to inappropriate, toxic multidrug NTM therapy—confirm first 1.
• Pitfall: Treating single, low-burden Microbacterium isolate as pathogen without corroboration; prioritize repeat cultures and source assessment per catheter guidelines to avoid overtreatment 7, 2, 3.
• Note: Microbacterium spp. are widely environmental and can colonize devices/dentures; detection alone does not equal disease 8, 2, 3.